Jagsonpal Pharmaceuticals Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,462 Cr
- P/E
- 31.11
- ROE
- 17.30%
- PEG
- 1.95
- Price to sales
- 4.97
- Debt to equity
- 0.03
- 52W high / low
- ₹244 / ₹161
- Sales growth (5Y)
- 8.85%
- EBITDA margin
- 20.80%
- Net profit margin
- 15.54%
- Promoter holding
- 69.06%
- Sales (last year)
- ₹294 Cr
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
Guidance scorecard · Q2 FY27 call
What Jagsonpal Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- Jagsonpal aims for mid-to-high teen growth in revenue, targeting to outgrow the Indian pharma market by 1.5x.
- Focus on organic growth through power brands like Indocap, Maintane, Endoreg, Pru, and Eukroma, which are outperforming their therapy markets.
- The company is enhancing productivity, operational excellence, and improving margins while growing sales.
- Expansion into the hospital segment via the acquisition of Aequitas Healthcare, targeting Rs.100 crores revenue from Aequitas by FY28-29.
- Cross-selling Jagsonpal’s branded products into the hospital network to drive incremental value.
- Pipeline includes launching innovative products with potential for first-in-India or breakthrough molecules expected to enhance premiumization.
- Gradual improvement of product mix toward higher gross margin products to enhance profitability.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
Up 2%+See what Jagsonpal Pharmaceuticals Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Jagsonpal Pharmaceuticals has been focusing on disciplined capital allocation balancing organic and inorganic growth.
- Over the last four years, the company generated over Rs.250 crores of operating cash used for strategic acquisitions like Yash Pharma (over Rs.90 crores).
- Recently acquired 85% stake in Aequitas Healthcare for Rs.20.8 crores to enter and expand in the hospital segment.
- Integration planning for Aequitas underway with expected synergies over the next 36 months.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Jagsonpal Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- The company is focusing on product mix improvement with higher gross margin products and some innovative products with pricing premium.
- There is an emphasis on increasing productivity and execution in the field to gradually improve gross margins.
- The hospital business (Aequitas) is expected to grow to about Rs.100 crores in revenue within 2.5 years with an EBITDA target of Rs.10 crores.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Jagsonpal Pharmaceuticals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Jagsonpal Pharmaceuticals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Jagsonpal Pharmaceuticals Ltd
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 68.48% | 68.09% | 68.04% | 67.98% | 67.82% | 67.77% | 67.65% | 67.54% | 67.39% | 67.89% | 69.06% | 68.82% |
| FIIs + | 0.53% | 0.73% | 1.10% | 2.30% | 2.10% | 2.10% | 2.17% | 2.12% | 2.12% | 2.44% | 2.30% | 2.13% |
| DIIs + | 0.82% | 0.84% | 0.84% | 0.11% | 0.00% | 0.00% | 0.05% | 0.08% | 0.15% | 0.22% | 0.62% | 1.64% |
| Public + | 30.16% | 30.33% | 30.01% | 29.63% | 30.10% | 30.11% | 30.12% | 30.25% | 30.34% | 29.44% | 28.04% | 27.40% |
| No. of Shareholders | 15,785 | 16,282 | 15,748 | 15,633 | 18,471 | 21,085 | 22,899 | 24,653 | 24,895 | 26,264 | 24,181 | 26,537 |
Financials of Jagsonpal Pharmaceuticals Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 | 81 |
| Expenses + | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 | 57 | 53 | 65 | 65 |
| Operating Profit | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 | 16 | 11 | 17 | 17 |
| OPM % | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% | 22% | 22% | 17% | 21% | 21% |
| Other Income + | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 | 1 | 3 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 | 17 |
| Tax % | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% | 25% | 25% | 25% | 25% |
| Net Profit + | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 | 13 |
| EPS in Rs | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 | 1.31 | 2.00 | 1.91 |
Financials of Jagsonpal Pharmaceuticals Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 287 | 301 |
| Expenses + | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 229 | 239 |
| Operating Profit | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 58 | 61 |
| OPM % | 6% | 8% | 4.0% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% | 20% |
| Other Income + | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 10 | 9 |
| Interest | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 | 9 |
| Profit before tax | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 58 | 61 |
| Tax % | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | 25% | |
| Net Profit + | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 43 | 45 |
| EPS in Rs | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 6.43 | 6.86 |
| Dividend Payout % | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% | 62% |
Financials of Jagsonpal Pharmaceuticals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 263 | 231 |
| Borrowings + | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 8 | 7 |
| Other Liabilities + | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 32 | 44 |
| Total Liabilities | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 | 295 |
| Fixed Assets + | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 85 | 82 |
| CWIP | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 | 20 |
| Other Assets + | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 231 | 194 |
| Total Assets | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 | 295 |
Financials of Jagsonpal Pharmaceuticals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4 | 9 | -3 | -2 | 31 | 11 | 28 | 7 | 47 | 35 | 55 | 47 |
| Cash from Investing Activity + | -0 | -2 | 41 | -3 | -1 | -11 | -2 | -26 | -58 | -25 | -45 | -36 |
| Cash from Financing Activity + | -1 | -6 | -34 | -1 | -6 | -1 | -7 | -18 | -0 | -9 | -12 | -12 |
| Net Cash Flow | 2 | 1 | 5 | -6 | 24 | -0 | 19 | -36 | -11 | 2 | -2 | -1 |
| Free Cash Flow | 4 | 6 | 40 | -5 | 30 | 12 | 28 | 6 | 48 | 35 | 90 | 47 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 53% | 83% | -6% | 14% | 311% | 150% | 164% | 54% | 158% | 189% | 124% | 101% |
Financials of Jagsonpal Pharmaceuticals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 | 22 |
| Inventory Days | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 | 51 |
| Days Payable | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 | 40 |
| Cash Conversion Cycle | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 | 33 |
| Working Capital Days | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 | 11 |
| ROCE % | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% | 23% |
Guidance history
How Jagsonpal Pharmaceuticals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Up 2%+ | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | None planned | — | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY26 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
29 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −0.2% | 60% |
| Last 6 months | +5.5% | 61% |
| Last 3 months | −6.0% | 51% |
The price is 27.1% below its all-time high of ₹304.44 (29 Nov 2024). Stocks more than 20% below their peak have their score halved, so 59 became 29.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Jagsonpal Pharmaceuticals Ltd: 0.4 × 60 + 0.4 × 61 + 0.2 × 51 = 59, halved to 29 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY